| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,855 |
9,300 |
$382K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,283 |
3,282 |
$229K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,706 |
4,517 |
$117K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,856 |
1,856 |
$109K |
| 69209 |
|
14 |
14 |
$10.39 |
| 81003 |
|
1,264 |
1,227 |
$6.17 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
334 |
332 |
$0.00 |
| 81002 |
|
766 |
744 |
$0.00 |
| 87913 |
|
228 |
225 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
82 |
75 |
$0.00 |
| 81025 |
|
32 |
32 |
$0.00 |
| 94760 |
|
268 |
265 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
779 |
759 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
105 |
103 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
406 |
394 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
25 |
25 |
$0.00 |
| 82962 |
|
29 |
29 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
13 |
13 |
$0.00 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
36 |
36 |
$0.00 |
| 99000 |
|
17 |
17 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12 |
12 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
13 |
12 |
$0.00 |